We present the first detailed study analysing OS in BMT for paediatric ALL following the introduction of high-resolution (HR) HLA matching. A total of 356 consecutive paediatric ALL stem cell transplants performed between 1988 and 2007 were reviewed; 80 of them were performed following the introduction of HR HLA class I and class II matching to the transplant programme in 2002. Comparisons of matched unrelated donor (MUD) transplant outcomes before and after this period were made. Matching at the HR level for HLA-A, -B, -C, -DRB1 and -DQB1 (HR-MUD) correlated with a greater than 25% improvement in 2-and 5-year OS in paediatric ALL patients transplanted with MUDs (P ¼ 0.009, P ¼ 0.005, respectively). Two-year OS for contemporaneous HLA-matched sibling transplants (80.8%) and HR-MUD transplants (78.8%) was equivalent. At 6%, non-relapse mortality (NRM) in MUD transplants since 2002 was significantly reduced compared with previous epochs. Changes in treatment and epoch-dependent improvements in outcome were reviewed for possible confounders to the influence of HR typing using univariate and multivariate analysis.
INTRODUCTION
Recently published retrospective studies indicate that matching at the HR level for HLA alleles between donors and recipients in unrelated haematopoietic SCT is associated with improved patient survival. 1 --7 These multi-centre studies looked retrospectively at stem cell transplants for which donors were initially selected using low/medium-resolution HLA typing. In a study of 1874 unrelated donor transplant pairs, 58% of the transplant pairs were matched at low resolution for HLA-A, -B, -C and -DR loci at the time of transplant. 1 Following retrospective HR typing of the transplant pairs, 34% of the pairs matched at low resolution had one or more mismatches at HR. Similarly in a cord blood transplantation study where patients and cord blood donations were typed at HR for HLA-DRB1 but were low resolution typed for HLA-A, -B at the time of transplant, retrospective HR typing of the HLA-A and -B loci resulted in demoting 32% of the match grades for the transplant pairs. 8 The overall impact of prospective HR matching for HLA upon an active paediatric transplant program has not been reported. The 2008 European Bone Marrow Transplant Handbook states that 'there are no reported studies that compare outcome of HLAidentical sibling donors with unrelated donors matched to the allelic level' for paediatric ALL. 9 The Bristol Royal Hospital for Children started selecting stem cell donors for transplantation on the basis of HLA HR matching with recipients in January 2002. Here we present the first detailed study analysing OS in paediatric ALL, where HLA HR matching of donor and recipient was performed prior to transplant.
MATERIALS AND METHODS Patients
Data were assessed on 356 consecutive ALL patients under the age of 18 years who received a stem cell transplant between 1988 and 2007. In all, 340 (95%) of the patients were White Caucasians and 8 (2%) Mixed Race. Other ethnic groups were below 1% of the patient cohort (3 Middle Eastern, 2 Afro-Caribbean, 2 Oriental and 1 Asian). This research was approved to meet NHS Blood and Transplant research group governance requirements.
HLA typing
A review of HLA typing over the duration of the transplant program revealed five distinct periods where typing methods changed. These were: adjusted for children under 4 years of age as previously described. 10 With the exception of sibling transplants, T-cell depletion was performed in all cases. From 1988 to 1999, unrelated donors in addition received Campath MoAb (Genzyme Corporation, Cambridge, MA, USA) (5 --20 mg/ day depending upon body weight) on days À9 to À5. In January 2000, the rat-derived Campath-1G Ab (Genzyme Corporation) was replaced with a humanised version Campath-1H (Alemtuzumab, Genzyme Corporation) (0.9 --1.0 mg/kg in 3 --4 doses). Stem cells from haplotype donors were T-cell depleted by Miltenyi CD34 þ cell selection as previously published.
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Data analysis
Data were grouped into five time periods (1988 --1992, 1993 --1995, 1996 --1999, 2000 --2001 and 2002 --2007) on the basis of evolving HLA-typing methods. Probability for OS was calculated using the Kaplan --Meier estimator, where death from any cause was considered an event. Patients were censored if they underwent a second transplant or were alive at last follow-up. Mean values and 95% CIs (confidence intervals) were reported for continuous variables and percentages for categorical variables. Interepoch variability around the mean for continuous values and possible trends in categorical data were analysed independently (Table 1) . Multivariate analysis to test covariate influence on 2-year OS using logistic regression and the Cox proportional hazards model 12, 13 were performed using SPSS software (version 17) . The following covariates were tested for possible confounding influence; disease status, patient/donor CMV serology combinations, patient age, patient/donor relationship and HLA match grade, stem cell source, days to engraftment, patient/donor sex b Analysis using chi-square test for trends.
combinations, GVHD and changes to pre-transplant conditioning protocol (Table 2) . Fine and Gray's method was used to analyse competing risks of disease relapse and non-relapse mortality (NRM). The disease status of the patients was categorised as follows: first complete clinical remission (CR1); second complete clinical remission (CR2); third and fourth complete clinical remission (XCR3).
Patients were considered as evaluable for engraftment if they survived 28 days post transplant. Neutrophil engraftment was defined as ANC X0.5 Â 10 9 /L on three consecutive measurements. Figure 2 ). Restricting analysis of OS to patients transplanted in CR2 since 2002 showed the matched sibling and the HR-MUD transplant 2-year OS to be identical ( Figure 3 ). In contrast, 2-year OS for mismatched transplants remained significantly inferior to that of sibling and HR-MUD transplants (Figures 2 and 3) . For transplants performed in CR2, OS haplo þ MMUD ¼ 38.5% vs MSD þ HR-MUD ¼ 87.5% (n ¼ 53, Po0.001) (Figure 3 ). There was a decrease in CMV seronegative patients receiving cells from seropositive donors (À/ þ ) after the year 2000, but differences in patient/donor CMV serological status had no significant impact on 2-year survival in both univariate and multivariate analysis (P40.1, Table 2 ).
RESULTS

HLA typing
The (Table 3) .
Relapse rate had a highly significant impact on OS and was significantly lower after 2002, but there was no statistically significant effect of HLA-matching grade on relapse rate independent of epoch ( Tables 1 and 3 epochs and did not impact upon 2-year survival (P ¼ 0.7, Tables 1  and 2 ). Analysis of variance from the mean age of patients in the five HLA-typing epochs showed patient age did not significantly impact 2-year survival (P ¼ 0.75). The percentage of patients in each disease status category (CR1 --3) at the time of transplantation was unchanged over time. CR2 had a reduced hazard ratio of 0.71 when compared with CR3 (95% CI ¼ 0.46 --0.98, P ¼ 0.09) and CR1 had a hazard ratio of 0.77 compared with CR3 but this did not reach statistical significance (95% CI ¼ 0.46 --1.19, P ¼ 0.24). Only two patients, transplanted prior to 2002, went on to second transplant following relapse; both subsequently died. The development of acute GVHD (aGVHD) was associated with decreased 2-year survival (P ¼ 0.001, Table 2 ). The incidence of GVHD was lower after 2002 in sibling, matched and mismatched transplants, but this failed to reach statistical significance (Tables 1  and 3 ). Of the patients who developed aGVHD in the HR typing epoch 86% survived at year 2 compared with only 25% for all other epochs combined (n ¼ 53; P ¼ 0.001, Table 1 ).
Epoch-dependent improvements in OS were seen in MSD, in part due to a reduced relapse rate since 2002, but this did not reach statistical significance (P ¼ 0.15, Table 3 ) or match the MUD to HR-MUD improvement observed with the introduction of HR matching (P ¼ 0.026, Figure 2 and Table 3) .
A Fine and Gray analysis of competing risks at 2 years post transplant examined the risk of relapse vs NRM ( Table 4) . The competing risk analysis showed that prior to 2002, only HLAmatched siblings had a significantly decreased hazard ratio for NRM compared with other donor sources. In the period from 2002 to 2007, there was no significant difference in competing risks for NRM between MSD and HR-MUD transplants but MMUD transplants had a significantly higher hazard ratio for NRM (hazard ratio ¼ 6.05, P ¼ 0.03). Thus, transplant outcomes for recipients with MUDs since 2002 are significantly different to prior epochs with a reduction in NRM from one that closely paralleled that of MMUD to one that is more closely aligned with MSD BMT.
DISCUSSION
In 1999, the Bristol Royal Hospital for Children reported that HLAmatched and -mismatched unrelated donor transplants had similar OS. 14 The current study confirms those earlier findings, but additionally reports significant subsequent improvement in OS for MUD transplants that parallels the introduction of HR HLA typing (HR-MUD).
For patients transplanted since 2002, HR-MUD and MSD OS were equivalent. In contrast, MMUD transplants have shown little improvement in OS when compared with the 1999 study (50% vs 40%, P ¼ 0.59), and are significantly worse than those of HR-MUD transplants. This was contrary to expectations as the literature states that a single HLA Ag or allele mismatch is well tolerated. 2, 15 The relapse rate in our study has fallen across all HLA-matching grades since 2002. The intrinsic risk of relapse due to disease-specific factors such as CR status and length of CR1 are well known to influence outcome from SCT. 16 In this study, there has been no change in the leukaemic risk profile (CR group or length of CR1 for CR2 patients) between epochs and between groups. The most likely reason for reduced relapse rates across all donor groups since 2002 is the more effective treatment and improved depth of remission prior to transplant seen with modern relapse therapy in the UK. 17 Although there has been a low relapse rate in both MSD and HR-MUD groups since 2002, their equivalence in outcome in the current era is a result of the reduction in NRM in the MUD group from a historical level of around 20% to 6%, comparable to the NRM of the matched sibling transplants (that has remained stable throughout epochs) of 3 --4% (Table 3) .
Our retrospective analysis of MUD donor recipient pairs prior to 2002 confirms that the introduction of HR typing has reduced the number of previous unidentified mismatches in the 'MUD' patients. The marked improvement in HR-MUD outcome has occurred at the same time as this reduction in mismatches and is a plausible explanation for the reduced NRM. However, other variables could also be responsible. We have therefore sought to identify any other effects that could explain our findings.
Some variables, such as CMV status of donor/recipient pairs and time to transplant, which are known to affect transplant outcomes, have been shown to have no effect ( Table 2 ). The change in Campath Ab is also unlikely to be responsible for the particular improvement in the HR-MUD cohort because (a) there was no improvement in survival seen in the year 2000 --2002 when the change to Campath-1H was made and (b) the change to Campath-1H was applied to both MUD and MMUD transplants and if this was causal we would have expected to see a similar improvement in the outcome of MMUD transplants.
Changes in supportive care could be responsible for some of the improvements seen. Survival following the diagnosis of GVHD has improved, which might partly be explained by more effective surveillance for and management of intercurrent infections. However, given the low incidence of aGVHD in the T-cell depleted transplant setting, this cannot explain all the reduction in NRM seen. There is some detectable time-dependent improvement in survival seen between epochs for sibling transplants, but relapse rather than NRM has always been the main reason for death post transplant in the sibling setting. If there were a general effect of improved supportive care then it would be expected across all subgroups. The lack of improvement in MMUD outcome since 2002 argues against improved supportive care independent of matching grade being the reason for the specific improvement in the HR-MUD group.
It is important to note that there has been no change in donor selection strategy to explain differences in outcome. All patients transplanted were eligible for transplant from any donor, and a strict hierarchy of related sibling, MUD (or HR-MUD) and then MMUD applied to all recipients. Therefore, we believe that one reason for improved outcomes in the HR-MUD group is due to the change to HR typing and a resulting reduction in NRM. Confirmation of this in other prospective studies would be important.
On comparing our data with the published literature, there are some notable differences.
The CIBMTR compared outcomes for paediatric transplants performed between 1993 and 2006 among MSD, mismatchedrelated donors (mmRD) and 8/8 (HLA-A, B, C, DRB1) HR-MUD BM transplants identified retrospectively. 7 The patients in this study had AML, ALL, CML or myelodysplasia (MDS) and all transplants were T-cell replete. Outcomes for MSD transplants were better than MUD or mmRD transplants. OS was 61% for MSD transplants, 51% for mmRD BMT and 50% for the HR-MUD BMT. TRM at 10% was lower for MSD than MUD (24%) or mmRD (27%). Grade 2 --4 aGVHD was observed in 29% of the MSD transplants, 56% of the mmRD transplants and 45% of the HR HLA-matched unrelated transplants. The results contrast with an aGVHD rate of o10% across all matching groups and a 2-year OS of 78.8% (HR-MUD) --80.8% (MSD) in the T-cell-depleted BM transplants reported in our study for patients transplanted since 2002.
The National Marrow Donor Panel (USA) examined survival in paediatric acute leukaemias transplants over a similar 20-year time Table 4 . Fine and Gray competing risks analyses for 2-year OS span to our study. 6 They report improved survival over time due to reduced TRM. They note particular improvement since 2003, which they ascribe to improved tissue-typing strategies. However, in marked contrast to our study, most of the improved survival was due to an approximate 30% improved survival in the MMUD transplant cohort transplanted between 2003 and 2006 compared with earlier periods.
In a recent cross-sectional study, it was reported that 100% of donors and recipients of allogeneic transplants performed in the UK were HR typed at HLA-DRB1 and -DQB1 (DPB1 matching was common at some centres), but only 40% were HR typed for HLA-A, -B and -C. Intermediate resolution typing and matching is still performed for 60% of allogeneic transplants at HLA-A, B and C. 18 In conclusion, we have shown that OS in unrelated donor paediatric ALL transplants improved significantly parallel to the introduction of prospective HR matching for HLA. In the context of T-cell-depleted transplants, with the associated low levels of GVHD and modern supportive care strategies, the introduction of prospective typing and matching at the HR level for HLA-A, -B, -C, -DRB1 and -DQB1 correlates with a significant reduction in NRM and a greater than 25% improvement in OS for HR-MUD compared with lower resolution typing methods, making HR-MUD outcomes comparable to MSD transplants for paediatric ALL patients. This improvement was not seen in the epoch where donor --recipient pairs were HR-matched at HLA-DRB1 and -DQB1 but intermediate-resolution matched for HLA-A, -B and -C (2000 --2001). The study findings are in agreement with earlier reports looking at retrospective HLA HR matching. The results in this study support the concept that donor selection guidelines for HLA matching in unrelated donor stem cell transplants for paediatric ALL transplants, where an unrelated BM or PBSC transplant is to be performed should require HR HLA typing and matching of donor and recipient at HLA-A, -B, -C, -DRB1 and -DQB1.
